Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alison Harrod
Observed names:
A Harrod,
Harrod, A,
Harrod, Alison,
Harrod, Alison Elizabeth
Institution:
Institute of Cancer Research
Observed institutions:
Institute of Cancer Research,
King's College London,
Breast Cancer Now,
Cancer Research UK,
Hammersmith Hospital,
Institute of Cancer Research,
Kings Health Partners,
University of Southampton,
Imperial College London
show all 9
ORCID:
0000-0002-3977-2791
Observed ORCID:
0000-0002-3977-2791
OpenAlex ID:
A5066555489
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
2016
·
A Harrod
, J Fulton
, et al.
·
Oncogene
·
186
PDF
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
2017
·
Lesley-Ann Martin
, Ricardo Ribas
, et al.
·
Nature Communications
·
173
PDF
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2018
·
Hetal Patel
, Manikandan Periyasamy
, et al.
·
Molecular Cancer Therapeutics
·
148
APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer
2015
·
Manikandan Periyasamy
, Hetal Patel
, et al.
·
Cell Reports
·
124
PDF
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
2016
·
Hetal Patel
, Rezvan Abduljabbar
, et al.
·
Clinical Cancer Research
·
106
The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks
2020
·
Alison Harrod
, Karen A. Lane
, et al.
·
DNA repair
·
68
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer
2022
·
Alison Harrod
, Chun-Fui Lai
, et al.
·
Oncogene
·
47
PDF
MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells
2021
·
Uttom Kumar
, Yunhui Hu
, et al.
·
Biochemical Pharmacology
·
24
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
2024
·
Tommaso De Marchi
, Chun-Fui Lai
, et al.
·
Scientific Reports
·
16
PDF
PBRM1 directs PBAF to pericentromeres and protects centromere integrity
2025
·
Karen A. Lane
, Alison Harrod
, et al.
·
Nature Communications
·
14
ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin
2025
·
Susana Simões-Sousa
, Noa Amin
, et al.
·
Cell Reports
·
7
PDF
CENP-B binds hairpin motifs in chromosome arms influencing gene expression
2026
·
Lillian Wu
, Karen A Lane
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
3
PDF
The SMARCA4 subunit of the SWI/SNF complex prevents genome instability at G quadruplexes
2026
·
Alison Harrod
, Hugang Feng
, et al.
·
Genome biology
·
2
Genome-wide Chromosome-specific Aneuploidy Engineering and Phenotypic Characterization with CRISPR-Taiji
2025
·
Hugang Feng
, Daqi Deng
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
2
PDF
Downs-Lab/SMARCA4_G4: SMARCA4_G4 publication
2026
·
A Harrod
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
The SMARCA4 subunit of the SWI/SNF complex prevents genome instability at G quadruplexes
2026
·
Harrod, Alison
, Feng, Hugang
, et al.
·
Figshare
Boundary issues: SWI/SNF shapes chromatin patterns in and around centromeres
2025
·
Karen A. Lane
, Alison Harrod
, et al.
·
Open Biology
PDF
Author response for "Boundary Issues: SWI/SNF shapes chromatin patterns in and around centromeres"
2025
·
Karen A. Lane
, Alison Harrod
, et al.
·
Publons reviews and discussion
Supplementary Figure S6. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Supplementary Figure S5. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Supplementary Information from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Supplementary Figure S3. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Supplementary Figure S7. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Supplementary Figure S4. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Supplementary Figure S2. from ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
2023
·
Hetal Patel
, Manikandan Periyasamy
, et al.
Show more works
View as search
Works count:
37
Citation count:
921
H-index:
10
I10-index:
10
Year
Topic
Type